Burris H A
Sarah Cannon Research Institute, Nashville, TN 37203, USA.
Oncogene. 2009 Aug;28 Suppl 1:S4-13. doi: 10.1038/onc.2009.196.
Non-small-cell lung cancer (NSCLC) is a major global health problem and is the leading cause of cancer death worldwide. Current treatment involves nonspecific, nonselective cytotoxic chemotherapy, which results in only a modest increase in survival and causes significant toxicity to the patient. Targeted agents are initially effective in certain small subpopulations of patients, but eventually nearly all patients become resistant to further treatment. The limitations in efficacy and safety associated with available treatments for NSCLC underscore the need for novel agents with improved efficacy and safety profiles. This review discusses the limitations of currently recommended therapies for patients with advanced NSCLC and discusses new agents in clinical development for this disease.
非小细胞肺癌（NSCLC）是一个重大的全球健康问题，也是全球癌症死亡的主要原因。目前的治疗方法包括非特异性、非选择性的细胞毒性化疗，其仅使生存率适度提高，并给患者带来显著毒性。靶向药物最初在某些小部分患者中有效，但最终几乎所有患者都会对进一步治疗产生耐药性。与NSCLC现有治疗方法相关的疗效和安全性限制凸显了对具有改善疗效和安全性的新型药物的需求。本综述讨论了目前推荐的晚期NSCLC患者治疗方法的局限性，并探讨了针对该疾病正在临床开发的新型药物。
